Format

Send to

Choose Destination
Bioorg Med Chem. 2011 May 15;19(10):3086-95. doi: 10.1016/j.bmc.2011.04.008. Epub 2011 Apr 7.

Virtual screening and further development of novel ALK inhibitors.

Author information

1
Drug Discovery Department, Research & Development Division, PharmaDesign, Inc., Hatchobori, Chuo-ku, Tokyo, Japan. okamoto@pharmadesign.co.jp

Abstract

Anaplastic lymphoma kinase (ALK) has been in the spotlight in recent years as a promising new target for therapy of non-small-cell lung cancer (NSCLC). Since the identification of the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene in some NSCLC patients was reported in 2007, various research groups have been seeking ALK inhibitors. Above all, crizotinib (PF-02341066) has been under clinical trial, and its therapeutic efficacy of inhibiting ALK in NSCLC has been reported. Among anticancer drugs, drug resistance appears frequently necessitating various kinds of inhibitors. We identified novel ALK inhibitors by virtual screening from the public chemical library collected by the Chemical Biology Research Initiative (CBRI) at the University of Tokyo, and inhibitors that are more potent were developed.

PMID:
21515061
DOI:
10.1016/j.bmc.2011.04.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center